DavidWilliamZenkMD

Oncology • Cedar Rapids, IA

Internal Medicine, Oncology and Hematology at Grand River Medical Group

Join to view full profile

Are you Dr. Zenk?

Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.

Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
You already have 59 invites waiting!
Read the latest clinical news, personalized to your specialty.

Claim this profile

Not you? Find your profile

Office
202 10th St SE
Cedar Rapids, IA 52403
Phone+1 319-297-2900

Fax+1 319-297-2969

Summary

Dr. David Zenk, MD is an oncologist in Cedar Rapids, Iowa. He is currently licensed to practice medicine in Iowa. He is affiliated with UnityPoint Health - St. Luke's Hospital and Mercy Medical Center - Cedar Rapids.

Education & Training

University of Iowa Hospitals and ClinicsFellowship, Hematology and Medical Oncology, 1987 - 1990
Mayo Clinic College of Medicine and Science (Rochester)Residency, Internal Medicine, 1984 - 1987
Creighton University School of MedicineClass of 1984

Certifications & Licensure

IA State Medical License 1987 - 2018

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification MOSAIQ EMR, Elekta, 2012-2013

Clinical Trials

Cytogenetic Studies in Acute Leukemia and Multiple Myeloma Start of enrollment: 1984 Jun 01
Active, not recruiting
Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy Start of enrollment: 2008 Nov 10
Active, not recruiting
Phase 3
Bevacizumab or Pemetrexed Disodium Alone or In Combination After Induction Therapy in Treating Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer Start of enrollment: 2010 Oct 25
Completed
Phase 3
S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery Start of enrollment: 2011 Apr 01
Active, not recruiting
Phase 3
Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Celecoxib in Treating Patients With Stage III Colon Cancer Previously Treated With Surgery Start of enrollment: 2010 Jun 01
Active, not recruiting
Phase 3
Ofatumumab in Treating Patients With Previously Untreated Stage II, Stage III, or Stage IV Follicular Non-Hodgkin Lymphoma Start of enrollment: 2011 Aug 01
Completed
Phase 2
Join now to see all

Publications & Presentations

PubMed

54 citations
A Phase II study of Bcl-2 antisense (oblimersen sodium) combined with gemtuzumab ozogamicin in older patients with acute myeloid leukemia in first relapse.
Joseph O. Moore, Karen Seiter, Jonathan E. Kolitz, Wendy Stock, Francis J. Giles
Leukemia Research. 2006-07-01
26 citations
Avian nuclear matrix proteins bind very tightly to cellular DNA of the beta-globin gene enhancer in a tissue-specific fashion.
Timothy W. Brotherton, David W. Zenk, Stephen Kahanic, Jeff Reneker
Biochemistry. 1991-06-18
25 citations
A nuclear matrix protein binds very tightly to DNA in the avian beta-globin gene enhancer.
David W. Zenk, Gordon D. Ginder, Timothy W. Brotherton
Biochemistry. 1990-06-05